Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

MRNABullishIndustry Newsnews

High materiality8/10

Moderna Gains on ESMO Melanoma Data for Intismeran Autogene

Sep 21, 2026, 1:58 PM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

High-profile ESMO data readouts and investor event could drive near-term upside; past spikes around vaccine/oncology data announcements have caused volatile moves, though outcome risk remains tied to data strength.

AI summary

What happened, with direct paths to the underlying reporting

Moderna disclosed three abstracts on intismeran autogene at ESMO, including Phase 3 data with Keytruda in adjuvant melanoma. The Presidential Symposium presentation on Oct 24 could clarify the therapy’s incremental benefit and shape sentiment for MRNA's oncology pipeline. An investor session the same day and the stock's recent volatility warrant close attention to data signals and timing.

Three intismeran autogene abstracts accepted for ESMO Congress.
Phase 3 INTerpath-001 data with Keytruda to be presented Oct 24.
Live investor session Oct 24 at 1 p.m. EDT; recording available 30 days.
MRNA surged to ~$169 after volatile August move; near 52-week high.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Moderna Gains on ESMO Melanoma Data for Intismeran Autogene

Moderna rallies on Phase 3 melanoma win; potential neoantigen vaccine milestone

Moderna's melanoma vaccine advances; market potential by 2027 with Merck collaboration

Moderna Announces Major Private Debt Offering, Shares Fall on Term Disclosure

FDA Approves Moderna 2026-27 COVID Vaccines, Boosting Near-Term Prospects